Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The effect of aggressive versus standard lipid lowering by atorvastatin ondiabetic dyslipidemia - The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia
Autore:
Berkplanken, I; Hoogerbrugge, N; Jansen, H; Jansen, H; Princen, HMG; Huisman, MV; van de Ree, MA; Stolk, RP; van Venrooij, FV; Banga, JD; Dallinga-Thie, G; van Venrooij, FV;
Indirizzi:
Univ Utrecht, Med Ctr, Julius Ctr Patient Oriented Res, NL-3508 GA Utrecht, Netherlands Univ Utrecht Utrecht Netherlands NL-3508 GA 3508 GA Utrecht, Netherlands Erasmus Med Ctr, Dept Internal Med, Rotterdam, Netherlands Erasmus Med Ctr Rotterdam Netherlands ernal Med, Rotterdam, Netherlands Erasmus Univ, Dept Biochem, NL-3000 DR Rotterdam, Netherlands Erasmus Univ Rotterdam Netherlands NL-3000 DR DR Rotterdam, Netherlands Erasmus Univ, Dept Clin Chem, NL-3000 DR Rotterdam, Netherlands Erasmus Univ Rotterdam Netherlands NL-3000 DR DR Rotterdam, Netherlands TNO, PG, Gaubius Lab, Leiden, Netherlands TNO Leiden NetherlandsTNO, PG, Gaubius Lab, Leiden, Netherlands Leiden Univ, Med Ctr, NL-2300 RA Leiden, Netherlands Leiden Univ Leiden Netherlands NL-2300 RA NL-2300 RA Leiden, Netherlands Univ Utrecht, Med Ctr, Julius Ctr Gen Practice & Patient Oriented Res, NL-3508 GA Utrecht, Netherlands Univ Utrecht Utrecht Netherlands NL-3508 GA 3508 GA Utrecht, Netherlands Univ Utrecht, Med Ctr, Div Internal Med, NL-3508 GA Utrecht, Netherlands Univ Utrecht Utrecht Netherlands NL-3508 GA 3508 GA Utrecht, Netherlands
Titolo Testata:
DIABETES CARE
fascicolo: 8, volume: 24, anno: 2001,
pagine: 1335 - 1341
SICI:
0149-5992(200108)24:8<1335:TEOAVS>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR MORTALITY; TRIGLYCERIDE ISSUE; GLUCOSE-TOLERANCE; RISK-FACTORS; HYPERCHOLESTEROLEMIA; SIMVASTATIN; HYPERTRIGLYCERIDEMIA; EFFICACY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Stolk, RP Univ Utrecht, Med Ctr, Julius Ctr Patient Oriented Res, DO1-335,POB 85500,NL-3508 GA Utrecht, Netherlands Univ Utrecht DO1-335,POB 85500 Utrecht Netherlands NL-3508 GA s
Citazione:
I. Berkplanken et al., "The effect of aggressive versus standard lipid lowering by atorvastatin ondiabetic dyslipidemia - The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia", DIABET CARE, 24(8), 2001, pp. 1335-1341

Abstract

OBJECTIVE - In patients with type 2 diabetes, intensive glucose regulation, although effective for microangiopathy, has not been shown to have unambiguous preventive effects on the occurrence of cardiovascular disease. Patients with diabetes show a characteristic dyslipidermia (high triglyceride level, low HDL cholesterol level). Aggressive reduction of triglycerides might be an effective method to reduce the cardiovascular risk in these patients. RESEARCH DESIGN AND METHODS - A double-blind, placebo-controlled ran, domized study to assess the effect of 30 weeks of administration of atorvastatin 10 and 80 mg on plasma triglyceride levels in 217 patients with type 2 diabetes and fasting triglyceride levels between 1.5 and 6.0 mmol/l. RESULTS - Administration of atorvastatin 10 and 80 mg resulted in significant reductions (25 and 35%, respectively) of plasma triglyceride levels (both P < 0.001). The difference between 10 and 80 mg was not statistically significant (P > 0.5). Atorvastatin 10 mg provided significant reductions from baseline in total cholesterol (-30%, P < 0.001), LDL cholesterol (-40%, P< 0.001), and apolipoprotein B (-31%, P < 0.001), and significantly increased HDL cholesterol from baseline by 6% (P < 0.005). Atorvastatin 80 mig had a similar effect on HDL cholesterol (+5.2%, P < 0.005) but significantly decreased total cholesterol (-40%, P < 0.001), LDL cholesterol (-52%, P < 0.001), and apolipoprotein B (-40%, P < 0.001) more than atorvastatin 10 mg (P < 0.005). The side effects of atorvastatin 10 and 80 mg were similar anddid not differ from the patients receiving placebo. CONCLUSIONS - Administration of 10- and 80-mg doses of atorvastatin provides similar, significant reductions from baseline in triglyceride levels in patients with type 2 diabetes. A higher dose of atorvastatin improves cholesterol-related parameters. Both doses were well tolerated in this patient population.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 17/01/20 alle ore 20:17:55